Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.
The amount of data investors digest daily on Wall Street can sometimes feel overwhelming. Over the last six weeks, investors have navigated their way through earnings season, a Federal Reserve Open Market Committee meeting, and President Donald Trump's regularly changing tariff and trade policy. Suffice it to say, it can be easy for something important to fall through the cracks.
Arguably the most important data dump of the entire quarter occurred less than two weeks ago on May 15. This marked the deadline for institutional investors with at least $100 million in assets under management to file Form 13F with the Securities and Exchange Commission.
A 13F is filing that allows professional and everyday investors to see which stocks Wall Street's smartest money managers purchased and sold in the latest quarter. Even though 13Fs have their flaws -- since they're filed 45 days after the end to a quarter, they may contain stale data for active hedge funds -- they still provide invaluable clues as to which stocks and trends have the full attention of the market's leading asset managers.
